---
document_datetime: 2023-09-21 22:05:06
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/nitisinone-mdk-previously-nitisinone-mendelikabs-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: nitisinone-mdk-previously-nitisinone-mendelikabs-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.8614341
conversion_datetime: 2025-12-21 18:58:45.447406
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Nitisinone MDK

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                   | Opinion/ Notification 1 issued on Commission Decision Issued 2 / amended on 22/04/2022 product   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                     |
|----------------------|-----------------------------------------|--------------------------------------------------------------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0013               | Renewal of the marketing authorisation. | 15/07/2022                                                                                       | SmPC and PL                      | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Nitisinone MDK in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions

are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IAIN/0014          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing         | 20/06/2022   | n/a        | authorised                        |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------------------|
| X/0007             | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                     | 14/10/2021   | 20/12/2021 | SmPC, Annex II, Labelling         |
| PSUSA/2169/ 202102 | Periodic Safety Update EU Single assessment - nitisinone                                                                                                                                                                                       | 30/09/2021   | n/a        | PRAC Recommendation - maintenance |
| IAIN/0011          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing         | 19/10/2020   | n/a no     | longer                            |
| IAIN/0010          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing product | 22/06/2020   | 17/06/2021 | Annex II and PL                   |
| T/0009             | Transfer of Marketing Authorisation                                                                                                                                                                                                            | 18/03/2020   | 28/04/2020 | SmPC, Labelling and               |
| IB/0006/G          | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a Medicinal                                                                                                                                 | 11/09/2019   | 28/04/2020 | PL SmPC and PL                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | longer authorised                 |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| IA/0005   | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size 26/06/2019                                                                                                                                                                                                                                                                                                   | n/a no                            |
| IB/0003   | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product 21/06/2019 Change in test procedure for AS or Medicinal product                                                                                                                                                                                                                                                                                  | 28/04/2020 SmPC, Labelling and PL |
| IA/0004/G | This was an application for a group of variations. B.I.b.2.a - starting material/reagent/intermediate changes to B.I.b.2.a - starting material/reagent/intermediate changes to 06/06/2019                                                                                                                                                                                                                                                                                 | n/a                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             | changes to an approved test procedure B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                               | longer authorised                                      |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| IB/0002/G   | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                    | 21/04/2018 20/09/2018 SmPC no                          |
| IAIN/0001/G | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Medicinal product | 03/10/2017 20/09/2018 SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

<!-- image -->